BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs

Affiliations

¹ Rheumatology Department, Portsmouth NHS Hospitals Trust, Portsmouth.
² Rheumatology Department, King's College Hospital NHS Foundation Trust, London.
³ Rheumatology Department, Central Manchester University Hospitals NHS Foundation Trust, Manchester.
⁴ National Rheumatoid Arthritis Society, Maidenhead.
⁵ Rheumatology Department, Epsom and St Helier University Hospitals NHS Trust, Epsom.
⁶ South Brent Health Centre, South Brent, Devon.
⁷ North Street Medical Practice, Peterborough.
⁸ Rheumatology Department, Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool.
⁹ Department of Pharmacy, Guy's and St Thomas' Hospital NHS Foundation Trust, London.
¹⁰ School of Health Sciences, University of East Anglia, Norwich, UK.
¹¹ Rheumatology Department, Radboud University Medical Centre, Nijmegen, Netherlands.
¹² Rheumatology Department, King's College London, London, UK.

Practice Guideline

Jo Ledingham et al. Rheumatology (Oxford). 2017.

. 2017 Jun 1;56(6):865-868.

doi: 10.1093/rheumatology/kew479.

¹ Rheumatology Department, Portsmouth NHS Hospitals Trust, Portsmouth.
² Rheumatology Department, King's College Hospital NHS Foundation Trust, London.
³ Rheumatology Department, Central Manchester University Hospitals NHS Foundation Trust, Manchester.
⁴ National Rheumatoid Arthritis Society, Maidenhead.
⁵ Rheumatology Department, Epsom and St Helier University Hospitals NHS Trust, Epsom.
⁶ South Brent Health Centre, South Brent, Devon.
⁷ North Street Medical Practice, Peterborough.
⁸ Rheumatology Department, Blackpool Teaching Hospitals NHS Foundation Trust, Blackpool.
⁹ Department of Pharmacy, Guy's and St Thomas' Hospital NHS Foundation Trust, London.
¹⁰ School of Health Sciences, University of East Anglia, Norwich, UK.
¹¹ Rheumatology Department, Radboud University Medical Centre, Nijmegen, Netherlands.
¹² Rheumatology Department, King's College London, London, UK.

Erratum in

BSR and BHPR guideline for the prescription and monitoring of non-biologic disease-modifying anti-rheumatic drugs.
Ledingham J, Gullick N, Irving K, Gorodkin R, Aris M, Burke J, Gordon P, Christidis D, Galloway S, Hayes E, Jeffries A, Mercer S, Mooney J, van Leuven S, Galloway J. Ledingham J, et al. Rheumatology (Oxford). 2017 Dec 1;56(12):2257. doi: 10.1093/rheumatology/kex389. Rheumatology (Oxford). 2017. PMID: 29029272 No abstract available.

No abstract available

Keywords: DMARDs; co-morbidity; drug toxicity; methotrexate; rheumatic disease; safe prescribing; shared care; treatment monitoring.